|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
21 CFR Part 11: (Un)Expected Added Value
By Joseph F. Noferi, Esq., Ralph Dillon, and Daniel E. Worden, pp. 44-50. Implementing the ERES rule will do more than make your organization compliant with federal regulations. It will strengthen its intellectual property position for the information age.
Advertisement
Articles in this issue
over 23 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 23 years ago
The Immunogenicity of Therapeutic Proteinsover 23 years ago
Inside Washington: Costs and Controls Challenge ManufacturersNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
